Peptides Vietnam LogoPeptides Vietnam
SemaglutideEducation, not adviceUpdated Oct 2026

Microdosing Semaglutide (Ozempic): Does It Work? Risks

Microdosing semaglutide means taking a dose below the 0.25 mg once-weekly step that the Wegovy and Ozempic labels use to start treatment (labelled dose, not a recommendation, Ozempic and Wegovy FDA labels), or spacing doses further apart than the labelled weekly schedule.124 PubMed searches on 2026-09-29 found no randomised clinical trial testing that practice in the marketed once-weekly pens.20 It is an off-label, community and telehealth driven idea, and the peer-reviewed commentary that reviews it calls the high-quality evidence essentially absent (microdosing commentary, PMID 42788826),4 while a physician essay in STAT News says there are no legitimate long-term data behind it and not even a single definition.17 This page lays out what the term means, what the Wegovy and Ozempic labels actually direct, what a phase 2 dose-finding trial showed at its lowest once-daily arms, why milligram-to-unit conversions depend on concentration, the techniques people describe, and the documented risks. It is education, not advice, and it does not tell anyone what to take.

This is general education, not medical advice, and not a dose to copy. Cedars-Sinai reports no standard dose or agreed-upon protocol for microdosing GLP-1s. PubMed searches on 2026-09-29 found no randomised clinical trial testing microdosing in the marketed once-weekly semaglutide pens.1320 Each figure on this page is a step from an approved label, an arm from a clinical trial, an example the FDA reported, or a definition or prevalence figure from a named secondary source, reported as the label, the trial, or the FDA stated it. The table below reports the FDA label's escalation schedule as labelled information, not a starting dose, schedule, or protocol for you to follow. If you are weighing any of this, the decision belongs with a licensed clinician, not a webpage.

Off-label

Not an FDA-approved use of semaglutide (TODAY, source 18)

No trial found

of microdosing the marketed weekly pens in PubMed searches on 2026-09-29 (source 20)

Boxed warning

thyroid C-cell tumors, on the Ozempic and Wegovy labels (sources 1 and 2)

What Microdosing Semaglutide Means

Microdosing is not a formal clinical term. In medicine it generally refers to taking a dose lower than the lowest approved dose of a medicine, and for GLP-1 drugs it has come to mean intentionally taking less than the labelled amount (Yale Medicine; Cleveland Clinic).1211 The peer-reviewed commentary by Beck and Clements describes a typical definition of microdosing: using 25 to 50% of manufacturer-recommended starting doses, or extending dosing intervals (community practice, no trial).4 This page does not convert that percentage into a milligram dose.

Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist sold as three FDA-approved products: Wegovy, Ozempic, and Rybelsus, an oral tablet (FDA MedWatch alert, source 8).8 Ozempic, for type 2 diabetes, and Wegovy, for weight management and related indications, both start at the same 0.25 mg once-weekly step, so microdosing, as the term is used online, means going below or staying under that 0.25 mg starting step (labelled dose, not a recommendation, Ozempic and Wegovy FDA labels).12 Microdosing is also considered off-label use, prescribing an approved drug for an unapproved purpose, which clinicians may do when they judge it appropriate (TODAY).18

Several clinicians make a point of separating microdosing from ordinary titration. Starting low and stepping up on an approved schedule is titration, as described in the Ozempic and Wegovy labels cited in the paragraph above (sources 1 and 2). Cedars-Sinai makes the point from the other side: what people call microdosing is usually titration, taking smaller amounts of approved medications (Cedars-Sinai).13 MU Health Care describes microdosing as taking a dose below the lowest approved dosage, sometimes progressing at a different pace than the label recommends (MU Health Care).16 This page is the semaglutide-specific spoke; for the cross-drug picture across semaglutide and tirzepatide, see the microdosing GLP-1 hub.

What the Ozempic and Wegovy Labels Actually Say

The labels are the reference point microdosing is defined against, so it helps to see them exactly. These are the schedules the FDA-approved prescribing information lists, reported here as education, not as a recommendation.

For Ozempic, the type 2 diabetes product, the label directs clinicians to initiate at 0.25 mg injected subcutaneously once weekly for 4 weeks, then increase to 0.5 mg once weekly; the maintenance dosage is 0.5 mg, 1 mg, or 2 mg once weekly, and the maximum is 2 mg once weekly (labelled dose, not a recommendation, Ozempic FDA label).1 The label marks the 0.25 mg step as Initiation, not a maintenance dose (labelled dose, not a recommendation, Ozempic FDA label); that labelled starting step is only a beginning, which is why the practice is described as sitting below it.1

For Wegovy, the weight-management product, the label sets a starting dosage of 0.25 mg once weekly for 4 weeks, then titrates every 4 weeks along the schedule below (labelled dose, not a recommendation, Wegovy FDA label).2

Read the steps below as labelled information, not a recommendation. These are the titration steps in the current DailyMed Wegovy label (source 2). After the maintenance step, the same label allows a maximum of 7.2 mg once weekly for adult weight reduction, and only for patients who have tolerated 2.4 mg for at least 4 weeks and in whom additional weight reduction is clinically indicated (labelled dose, not a recommendation, Wegovy FDA label). The decision to start, hold, or move belongs with a prescriber, not a webpage.

WeekWegovy labelled once-weekly dosage
Week 1 to 40.25 mg once weekly (labelled dose, not a recommendation, Wegovy FDA label)
Week 5 to 80.5 mg once weekly (labelled dose, not a recommendation, Wegovy FDA label)
Week 9 to 121 mg once weekly (labelled dose, not a recommendation, Wegovy FDA label)
Week 13 to 161.7 mg once weekly (labelled dose, not a recommendation, Wegovy FDA label)
Week 17 and onwardThe label lists maintenance for adult weight reduction as 1.7 mg or 2.4 mg (recommended) once weekly (labelled dose, not a recommendation, Wegovy FDA label).

The Wegovy label allows a later increase for adults who tolerate 2.4 mg for at least 4 weeks (labelled dose, not a recommendation, Wegovy FDA label) and for whom additional weight reduction is clinically indicated, to a maximum of 7.2 mg once weekly (labelled dose, not a recommendation, Wegovy FDA label). This is conditional, not the week-17 step. The two products are supplied differently, which matters when comparing concentrations. The current DailyMed Wegovy label lists single-dose pens that each deliver one preset dose, 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and a 7.2 mg per 0.75 mL high-dose pen (WEGOVY HD), plus single-dose syringes of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg (labelled dose, not a recommendation, Wegovy FDA label).2 Because each of those single-dose pens and syringes is preset, it delivers one fixed dose and provides no labelled way to select a fraction of it. The label also lists one single-patient-use multidose pen, WEGOVY FlexTouch, 9.6 mg in 3 mL which is 3.2 mg/mL, but it only delivers four fixed 2.4 mg doses; its instructions say to turn the dose selector until the counter shows 2.4 mg and, verbatim, "Do not set the dose by counting the number of clicks you hear," so it is not a low-dose device either (labelled dose, not a recommendation, Wegovy FDA label).2 Ozempic comes as multiple-dose pens for single-patient use in three strengths, each at a fixed concentration: 2 mg in 3 mL, labelled at 0.68 mg/mL; 4 mg in 3 mL, labelled at 1.34 mg/mL; and 8 mg in 3 mL, labelled at 2.68 mg/mL (labelled dose, not a recommendation, Ozempic FDA label).1

Ozempic is also supplied as single-dose prefilled syringes of 0.25 mg, 0.5 mg, or 1 mg per 0.5 mL (labelled dose, not a recommendation, Ozempic FDA label).1 Wegovy is additionally available as tablets of 1.5 mg, 4 mg, 9 mg, and 25 mg, though oral dosing sits outside this discussion of injections (labelled dose, not a recommendation, Wegovy FDA label).2

What the Low-Dose Trial Arms Showed

The closest thing to evidence on low doses of semaglutide for weight is a single phase 2 dose-finding trial, published by O'Neil and colleagues in the Lancet in 2018 (trial, PMID 30122305); dated PubMed searches found no other dedicated dose-finding weight trial (PubMed search, source 20).320 It was a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial in 957 adults without diabetes and with a body-mass index of 30 or more, with percentage weight loss at week 52 as the primary endpoint (trial, PMID 30122305).3

One detail decides how much this trial can say about microdosing. The dose arms were semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg, and 0.4 mg per day, initiated at 0.05 mg per day and escalated every 4 weeks (trial dose, not a recommendation, PMID 30122305). All of those doses were given once daily, by subcutaneous injection, using an investigational daily formulation, not the once-weekly pens sold today. So this is a dose-response study of a daily drug, not a study of microdosing the weekly pens, and its milligram figures cannot be read across to a weekly dose.

Within that daily design, even the lowest arms beat placebo. Estimated mean weight loss at week 52 was about 2.3% on placebo, against 6.0% at 0.05 mg per day, 8.6% at 0.1 mg per day, 11.6% at 0.2 mg per day, 11.2% at 0.3 mg per day, and 13.8% at 0.4 mg per day (trial dose, not a recommendation, PMID 30122305).3 Weight loss of 10% or more occurred in about 10% of the placebo group versus 37 to 65% of those on 0.1 mg per day or more of semaglutide, and the reductions at 0.2 mg per day or more were significantly greater than those with the liraglutide 3.0 mg per day comparator (trial dose, not a recommendation, PMID 30122305). What that shows is a clear dose-response, not validation of any specific microdose of the marketed weekly products.

The trial also reported that all semaglutide doses were generally well tolerated with no new safety concerns in that once-daily trial, and that the most common adverse events were dose-related gastrointestinal symptoms, primarily nausea (trial, PMID 30122305).3 That dose-related nausea is the tolerability rationale people cite for staying low, and it is echoed in the microdosing commentary (microdosing commentary, PMID 42788826).4

Does Microdosing Semaglutide Work?

Whether it works has not been established. PubMed searches on 2026-09-29 found no randomised trial of microdosing the marketed once-weekly semaglutide pens for weight (PubMed search, source 20),20 and the review literature says so plainly: the commentary that surveys the practice calls the high-quality clinical evidence essentially absent and still limited (microdosing commentary, PMID 42788826),4 and a physician essay in STAT News goes further, saying microdosing is not a thing, that there are no legitimate long-term data to support it, and that there is not even a single definition.17

That does not mean nothing has been observed. Early real-world reports describe possible benefits, reduced nausea, improved adherence, and modest weight loss, but the same commentary is clear that these are reports, not controlled trials, and that safety concerns persist around compounded products, nonstandard dose measurement, and dosing accuracy (microdosing commentary, PMID 42788826).4 A 2026 narrative review gathered the available evidence on long-term GLP-1 microdosing, but a narrative review is a summary of existing reports, not a trial that tests the question (narrative review, PMID 42668762).6

Across major health systems and consumer reporting the stance is consistent and cautious. Cleveland Clinic says taking a smaller dose than prescribed is not a good idea and notes microdosing is not endorsed by the American Diabetes Association (Cleveland Clinic).11 Hackensack Meridian Health states there is no evidence that microdosing works to help people lose weight (Hackensack Meridian Health).14 Novant Health calls it a bad idea and all anecdotal (Novant Health).15 Yale Medicine says there is limited evidence supporting doses lower than those studied in trials, and that microdosing should not be the first option a person reaches for (Yale Medicine).12 MU Health Care frames the popular claims as myths and warns against experimenting outside a research setting (MU Health Care),16 and consumer reporting in TODAY quotes physicians calling GLP-1 microdosing experimental and a Wild West, with neither recommending it (TODAY).18

The topic is live in the specialist literature too: PubMed indexes a 2025 Diabetes Care article titled One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens (Diabetes Care, PMID 39808463).7 Its full text could not be retrieved, and PubMed lists no abstract, so this page cites its title only. The health systems cited above take a cautious view. The phase 2 trial found weight loss even at its lowest once-daily investigational doses (randomised trial, PMID 30122305). Whether microdosing the weekly pens works, and at what cost, has not been established.

Microdosing Semaglutide Chart: The Units and Milligram Math

The FDA warns milligram-to-unit conversions cause overdoses

The FDA reports patients measuring and self-administering five to 20 times the intended dose, including tenfold errors, when a small intended volume was misread on a U-100 syringe and milligrams, milliliters, and units were confused (FDA safety alert figure, not a recommendation).8 The same FDA alert says compounded concentrations vary by compounder and are not standardized, so no single chart fits every vial.

To turn a dose into syringe units for your own vial strength, use our semaglutide reconstitution calculator, which works from the concentration on your label.

Turning a labelled reference dose into a volume and a unit count depends entirely on the concentration of the vial in hand, and because compounded concentrations are not standardized, no fixed chart is safe to read a dose off (FDA MedWatch alert). MedlinePlus explains that insulin syringes are marked for U-100 insulin.19 That is the whole hazard: a very small intended volume, an unfamiliar syringe, and a concentration that varies by compounder, which together have driven the overdoses above. So the conversion for a specific vial belongs in a tool that takes that vial's concentration as input, not in a page. For the syringe markings themselves, the insulin syringe units chart lays out the U-100 scale, and the semaglutide reconstitution calculator handles a specific vial.

What People Actually Do, and Why

Because the labels publish no way to measure a fraction of a dose, microdosing relies on user-devised techniques. The commentary lists two: click counting on multidose pens, and extended-interval dosing, meaning spacing injections further apart (community practice, no trial; microdosing commentary, PMID 42788826).4

Click counting deserves a caution, because neither label publishes a clicks-per-dose measurement scheme, and both now warn against the practice. The current Ozempic label states that the dose selector clicks when turned and, verbatim, "Do not count the pen clicks." The current Wegovy FlexTouch label likewise says "Do not set the dose by counting the number of clicks you hear" and that only the 2.4 mg dose can be selected; the single-dose Wegovy pens separately describe two clicks you hear during the injection as injection-progress sounds, not a way to measure a dose (labelled dose, not a recommendation, Ozempic and Wegovy FDA labels).12 Counting clicks to hit a fraction of a dose is therefore a community workaround that the labels specifically caution against, not a labelled measurement feature (community practice, no trial).

People cite cost and access after the semaglutide shortage ended, and wanting only a small amount of weight loss, sometimes called vanity weight (microdosing dilemma, PMID 42201545).5 Gastrointestinal tolerability is another reason people give (microdosing commentary, PMID 42788826).4 A survey that included more than 8,000 GLP-1 users found that 15% had tried or were currently microdosing the drug, and nearly half did so without consulting their doctor (Hackensack Meridian Health).14

Trainer describes online sellers of illicit research-grade peptides and unregulated providers including medical spas (microdosing dilemma, PMID 42201545).5 A STAT News physician essay attributes the spread of the term to direct-to-consumer companies selling compounded products that are not FDA approved.17 Beck and Clements describe its uptake through telemedicine weight-loss programs (commentary, PMID 42788826, source 4). The reason compounded vials are in the picture at all is regulatory. The FDA determined the semaglutide injection shortage, which had run since 2022, resolved on February 21, 2025, and the enforcement discretion that had allowed wide compounding then ended, on April 22, 2025 for state-licensed pharmacies and May 22, 2025 for outsourcing facilities (FDA).9 A narrow lane remains, in which the FDA does not intend to act against a compounder that fills four or fewer prescriptions of an essentially copied product in a calendar month (FDA).9 Separately, Trainer ties ongoing affordability barriers to a shift toward unsupervised strategies such as microdosing (microdosing dilemma, PMID 42201545).5 Access and sourcing in Vietnam specifically are covered in the semaglutide in Vietnam guide, not here.

The Risks

The risks fall into two groups: the risks of semaglutide itself, from the labels and the trial, and the risks specific to microdosing, from the FDA and the microdosing literature.

Boxed warning, both products: thyroid C-cell tumors

In rodents, semaglutide causes thyroid C-cell tumors; whether it causes them, including medullary thyroid carcinoma, in humans is unknown (Ozempic and Wegovy FDA labels).12

The most common adverse reactions are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation (Ozempic FDA label),1 and in the phase 2 trial these were dose-related, primarily nausea (trial, PMID 30122305).3 The labelled warnings also include acute pancreatitis, with the instruction to discontinue if it is suspected, and hypoglycemia when semaglutide is combined with an insulin secretagogue or insulin (Ozempic FDA label).1 For a fuller walk-through of the common side effects and how they are usually managed, see the GLP-1 side effects guide.

Microdosing adds risks of its own. The commentary flags nonstandard dose measurement, dosing accuracy, compounded product quality, pen manipulation, compounded vials, and medication sharing (microdosing commentary, PMID 42788826; microdosing dilemma, PMID 42201545).45 The FDA has tied dosing errors with compounded injectable semaglutide to overdoses in which patients administered five to 20 times more than the intended dose, often by confusing milligrams, milliliters, and units (FDA safety alert figure, not a recommendation), and because semaglutide has a half-life of about one week, those effects can be prolonged (FDA MedWatch alert).8

The scale is not trivial. As of May 31, 2026 the FDA had received 990 reports of adverse events associated with compounded semaglutide (FDA).10 The agency also flags that some semaglutide salt forms, such as sodium and acetate, are different active ingredients than the approved drug, that FDA generally recommends discarding multiple-dose sterile vials within 28 days of first use, and that it is aware of counterfeit Ozempic marketed in the United States (FDA).10

The Short Version

  • Microdosing semaglutide means dosing below the labelled 0.25 mg once-weekly starting step, or holding under it (labelled dose, not a recommendation, Ozempic and Wegovy FDA labels). It is off-label (TODAY), with no standard dose or agreed-upon protocol (Cedars-Sinai). PubMed searches on 2026-09-29 found no randomised clinical trial testing it in the marketed weekly pens (source 20).
  • The peer-reviewed commentary that reviews the practice calls the high-quality evidence essentially absent (microdosing commentary, PMID 42788826); a STAT News physician essay says there are no legitimate long-term data behind it (STAT News).
  • The Ozempic label starts at 0.25 mg weekly as Initiation, then 0.5 mg, with maintenance of 0.5, 1, or 2 mg and a 2 mg maximum (labelled dose, not a recommendation, Ozempic FDA label). Wegovy titrates 0.25, 0.5, 1, 1.7, then a maintenance of 1.7 mg or 2.4 mg, and for adult weight reduction the current label allows up to 7.2 mg once weekly after 2.4 mg is tolerated for at least 4 weeks and additional weight reduction is clinically indicated (labelled dose, not a recommendation, Wegovy FDA label).
  • The one dedicated dose-finding weight trial, O'Neil 2018 (PubMed search, source 20), tested 0.05, 0.1, 0.2, 0.3, and 0.4 mg per day of an investigational once-daily formulation; the low arms showed significantly greater weight loss than placebo, but that is a daily drug, not the weekly pen, and not a microdosing study (trial dose, not a recommendation, PMID 30122305).
  • The FDA reports patients measuring and self-administering five to 20 times the intended dose (FDA safety alert figure, not a recommendation). It also reports that compounded concentrations vary by compounder (FDA MedWatch alert). For a specific vial, use the semaglutide reconstitution calculator.
  • Click counting is a community technique, not a labelled feature: the current Ozempic and Wegovy FlexTouch labels both tell users not to set a dose by counting pen clicks, and neither publishes a clicks-per-dose scheme (Ozempic and Wegovy FDA labels).
  • Both products carry a boxed warning for thyroid C-cell tumors (Ozempic and Wegovy FDA labels). The most common adverse reactions are gastrointestinal (Ozempic FDA label). Microdosing adds compounding, measurement, and product-quality risks (microdosing commentary, PMID 42788826).

Frequently asked questions

Does microdosing semaglutide work?+

PubMed searches on 2026-09-29 found no randomised clinical trial testing microdosing the marketed once-weekly semaglutide pens for weight loss (source 20). The peer-reviewed commentary that reviews the practice calls the high-quality evidence essentially absent and still limited (microdosing commentary, PMID 42788826), a physician essay in STAT News says there are no legitimate long-term data to support it and not even a single definition, and a 2026 narrative review that summarizes available evidence on GLP-1 effects and possible benefits of long-term microdosing is a summary, not a controlled trial (narrative review, PMID 42668762). Early real-world reports describe reduced nausea, better adherence, and modest weight loss, but they are reports, not controlled trials (microdosing commentary, PMID 42788826). The one dedicated dose-finding trial of semaglutide for weight, O'Neil 2018 (PubMed search, source 20), did show a clear dose-response even at its lowest arms, but those were once-daily investigational doses of 0.05 mg to 0.4 mg per day, not the weekly pens, and not a microdosing study (trial dose, not a recommendation, PMID 30122305).

What does microdosing semaglutide mean?+

Microdosing semaglutide means using a dose below the lowest labelled dose, the 0.25 mg once-weekly step that both the Ozempic and Wegovy labels use to start, or spacing doses further apart than the labelled weekly schedule (labelled dose, not a recommendation, Ozempic and Wegovy FDA labels). It is not a formal clinical term, and there is no standard dose or protocol (Yale Medicine; Cedars-Sinai). A peer-reviewed commentary describes a typical definition of microdosing: using 25 to 50% of manufacturer-recommended starting doses, or extending dosing intervals (community practice, no trial). The commentary is by Beck and Clements (PMID 42788826). This page does not convert that percentage into a milligram dose. Clinicians note that what people call microdosing is often just ordinary titration of an approved medicine (Cedars-Sinai).

Is microdosing semaglutide safe?+

Safety has not been established: PubMed searches on 2026-09-29 found no randomised clinical trial testing microdosing the marketed weekly pens (source 20). Semaglutide carries a boxed warning for thyroid C-cell tumors seen in rodents, with the human risk unknown (Ozempic and Wegovy FDA labels). Its most common adverse reactions are gastrointestinal (Ozempic FDA label). Microdosing adds its own risks: nonstandard dose measurement, dosing accuracy, compounded product quality, pen manipulation, and medication sharing (microdosing commentary, PMID 42788826; microdosing dilemma, PMID 42201545). The FDA has linked dosing errors with compounded injectable semaglutide to overdoses of five to 20 times the intended dose (FDA safety alert figure, not a recommendation), and because semaglutide has a half-life of about one week, those effects can be prolonged (FDA MedWatch alert).

How many units is a semaglutide microdose on an insulin syringe?+

There is no published microdose, so there is no unit figure to give. To turn a dose into syringe units for your own vial strength, use our semaglutide reconstitution calculator at /tools/semaglutide-reconstitution-calculator, which works from the concentration on your label. The FDA reports overdoses when a small intended volume was misread on the syringe or milligrams, milliliters, and units were confused. The FDA also warns that compounded concentrations are not standardized, so a chart is not a substitute for the concentration of the actual vial (FDA MedWatch alert).

Is microdosing semaglutide FDA approved?+

No. Microdosing is off-label use, meaning use of an approved drug in a way its label does not describe, which clinicians may do when they judge it appropriate (TODAY). Cedars-Sinai reports no standard dose or agreed-upon protocol for microdosing GLP-1s. The FDA safety alert describes injectable Wegovy and Ozempic as dosed in milligrams at standard concentrations, and Rybelsus as an oral tablet (FDA MedWatch alert, source 8). The Ozempic and Wegovy injection labels start at 0.25 mg once weekly (labelled dose, not a recommendation, Ozempic and Wegovy FDA labels).

Why do people microdose semaglutide?+

People cite cost and access after the semaglutide shortage ended, and wanting only a small amount of weight loss, sometimes called vanity weight (microdosing dilemma, PMID 42201545). Gastrointestinal tolerability is another reason people give (microdosing commentary, PMID 42788826). A survey that included more than 8,000 GLP-1 users found that 15% had tried or were currently microdosing the drug, and nearly half did so without consulting their doctor (Hackensack Meridian Health). None of that is evidence that it works.

Sources and references

  1. 1.Ozempic (semaglutide) injection, FDA-approved prescribing information (Novo Nordisk), revised 05/2026, via DailyMed (current SPL version 20, published June 10, 2026; Instructions for Use revised June/2026). Reference ID 5793040. Fetched 2026-09-29, re-checked 2026-09-30. DailyMed / Ozempic prescribing information
  2. 2.Wegovy (semaglutide) injection and tablets, FDA-approved prescribing information (Novo Nordisk), current DailyMed SPL version 19, published June 30, 2026 (SPL effective 2026-06-18), setid ee06186f-2aa3-4990-a760-757579d8f77b. Fetched 2026-09-30. DailyMed / Wegovy prescribing information
  3. 3.O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018;392(10148):637-649. PMID 30122305. PubMed PMID 30122305
  4. 4.Beck H, Clements JN. Considerations and challenges in microdosing of GLP-1-based receptor agonists. Expert Opinion on Pharmacotherapy, 2026 (ahead of print). PMID 42788826. PubMed PMID 42788826
  5. 5.Trainer N. The microdosing dilemma: balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. Journal of the American Association of Nurse Practitioners, 2026 (ahead of print). PMID 42201545. PubMed PMID 42201545
  6. 6.Panlilio MA, Piserchio N, Hennessey M, Torres K, Khan S, Choy L. Multisystem Benefits of GLP-1 Microdosing: A Narrative Review. Cureus 2026;18(7):e113635. PMID 42668762. PubMed PMID 42668762
  7. 7.Kome AM, Chandran MM, Tungate Lopez SS, Buse JB, Klein KR. One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens. Diabetes Care 2025;48(3):e25-e27. PMID 39808463. PubMed PMID 39808463
  8. 8.US Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products. MedWatch. Fetched 2026-09-29. fda.gov / compounded semaglutide dosing errors
  9. 9.US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current as of 04/01/2026. Fetched 2026-09-29. fda.gov / compounder policies as supply stabilizes
  10. 10.US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Fetched 2026-09-29. fda.gov / unapproved GLP-1 drugs
  11. 11.Cleveland Clinic health essentials. Microdosing GLP-1s. Fetched 2026-09-29. Cleveland Clinic / microdosing GLP-1s
  12. 12.Yale Medicine. Microdosing GLP-1 (and Accutane): What Does It Mean and Does It Work? Fetched 2026-09-29. Yale Medicine / microdosing GLP-1
  13. 13.Cedars-Sinai. Can Microdosing GLP-1s Promote Health and Weight Loss? Fetched 2026-09-29. Cedars-Sinai / microdosing GLP-1s
  14. 14.Hackensack Meridian Health. Is Microdosing GLP-1s Safe? Fetched 2026-09-29. Hackensack Meridian Health / is microdosing GLP-1s safe
  15. 15.Novant Health. Micro-dosing GLP-1 drugs is a bad idea, here's why. Fetched 2026-09-29. Novant Health / micro-dosing GLP-1 drugs
  16. 16.MU Health Care. Thinking about microdosing GLP-1? 5 Myths Debunked. Fetched 2026-09-29. MU Health Care / microdosing GLP-1 myths
  17. 17.STAT News. GLP-1 microdosing is popular but unsupported by evidence. Physician opinion essay, 2026-05-29. Fetched 2026-09-29. STAT News / GLP-1 microdosing
  18. 18.TODAY (NBC). GLP-1 microdosing for weight loss. Fetched 2026-09-29. TODAY / GLP-1 microdosing
  19. 19.MedlinePlus, US National Library of Medicine. Insulin, how to give a shot (insulin syringe units). Fetched 2026-09-29. MedlinePlus / insulin syringe units
  20. 20.PubMed search provenance (NCBI E-utilities), run 2026-09-29. Term "microdosing semaglutide" returned 9 records, of which 5 are microdosing commentary, reviews or letters and 4 are off-topic, with no randomized trial of microdosing the marketed once-weekly pens. Term "semaglutide AND (dose-ranging OR dose-finding) AND (obesity OR weight loss)" returned 5 records, of which only O'Neil 2018 is a dose-ranging weight-loss trial. A low-dose and subtherapeutic semaglutide search returned 30 records, none a sub-0.25 mg once-weekly maintenance weight trial. Basis for the statements that this is the one dedicated dose-finding weight trial and that these searches found no randomised clinical trial testing microdosing the marketed weekly pens. PubMed / microdosing semaglutide search provenance

Related reading

Microdosing GLP-1s

The cross-drug overview this page sits under

Microdosing Tirzepatide

The same questions for the other GLP-1 drug

Semaglutide Reconstitution Calculator

Concentration and volume for a specific vial

Semaglutide in Vietnam

Access and sourcing, covered separately

This guide is for educational purposes only and is not medical advice. It describes what the FDA-approved labels, published clinical trials, and the FDA reported; it is not an endorsement, a recommendation, or an instruction to use any compound at any dose. Microdosing semaglutide is off-label, and PubMed searches on 2026-09-29 found no randomised clinical trial testing it in the marketed once-weekly pens.20 Consult a qualified healthcare professional before making any decision about your health.

Sources

  1. 1.DailyMed / Ozempic prescribing information
  2. 2.DailyMed / Wegovy prescribing information
  3. 3.PubMed PMID 30122305
  4. 4.PubMed PMID 42788826
  5. 5.PubMed PMID 42201545
  6. 6.PubMed PMID 42668762
  7. 7.PubMed PMID 39808463
  8. 8.fda.gov / compounded semaglutide dosing errors
  9. 9.fda.gov / compounder policies as supply stabilizes
  10. 10.fda.gov / unapproved GLP-1 drugs
  11. 11.Cleveland Clinic / microdosing GLP-1s
  12. 12.Yale Medicine / microdosing GLP-1
  13. 13.Cedars-Sinai / microdosing GLP-1s
  14. 14.Hackensack Meridian Health / is microdosing GLP-1s safe
  15. 15.Novant Health / micro-dosing GLP-1 drugs
  16. 16.MU Health Care / microdosing GLP-1 myths
  17. 17.STAT News / GLP-1 microdosing
  18. 18.TODAY / GLP-1 microdosing
  19. 19.MedlinePlus / insulin syringe units
  20. 20.PubMed / microdosing semaglutide search provenance